Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-beyond-batten-disease-foundation-collaborate-to-advance-emerging-therapies-to-fight-juvenile-batten-disease-5317
Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center
Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-multi-year-contract-to-manage-national-cancer-institute-chemical-biology-consortium-screening-libraries-center-5315
Evotec AG increases its revenue guidance for 2015
Evotec AG today announced that it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-increases-its-revenue-guidance-for-2015-12
Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis
Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-licence-and-collaboration-agreement-with-pfizer-inc-in-tissue-fibrosis-5309
Evotec publishes update of its DDup Special Edition – Drug discovery services
Hamburg, Germany – 04 September 2015: Evotec AG today published its updated DDup Special edition “Drug discovery services”. This new edition outlines Evotec’s drug discovery platforms including new capacities, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-update-of-its-ddup-special-edition—drug-discovery-services-5306
Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint
Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-chdi-foundation-expand-ongoing-collaboration-to-fight-huntingtons-disease-using-evotecs-expanded-capabilities-and-footprint-5305
Evotec AG reports results of first half of 2015
Evotec AG today reported financial results and corporate updates for the first half of 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2015-5303
Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-apeiron-biologics-and-sanofi-jointly-develop-novel-small-molecule-based-cancer-immunotherapies-5301
Sanofi and Evotec align forces to develop next generation therapies in diabetes
Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/sanofi-and-evotec-align-forces-to-develop-next-generation-therapies-in-diabetes-5299
Evotec enters innovative research initiative with Gladstone Institutes and Dolby Family Ventures in Alzheimer's Disease
Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-innovative-research-initiative-with-gladstone-institutes-and-dolby-family-ventures-in-alzheimers-disease-5295